Malignancies: Pre and post transplantation strategies

Transplantation Reviews

Volumn 28, Issue 2, 2014, Pages 76-83

  AlBugami, Meteb ^a   Kiberd, Bryce ^b  

^a KING FAHAD SPECIALIST HOSPITAL   (Saudi Arabia)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL RECTAL EXAMINATION; DISEASE SURVEILLANCE; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; KIDNEY CANCER; LEUKEMIA; LIVER TRANSPLANTATION; LUNG CANCER; LYMPHOMA; MEDICAL EXPERT; MEDICAL HISTORY; NEOPLASM; OCCULT BLOOD TEST; ORGAN TRANSPLANTATION; PERSONALIZED MEDICINE; PHYSICAL EXAMINATION; POSTOPERATIVE CARE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SOLID ORGAN TRANSPLANTATION; CANCER STAGING; FEMALE; IMMUNOCOMPROMISED PATIENT; KIDNEY TRANSPLANTATION; MALE; NEOPLASMS; PATHOLOGY; PHYSIOLOGIC MONITORING; PREVALENCE; PROCEDURES; PROGNOSIS; SURVIVAL; TUMOR INVASION;

IMMUNOSUPPRESSIVE AGENT;

FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MONITORING, PHYSIOLOGIC; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS; ORGAN TRANSPLANTATION; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84897032631     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2013.12.002     Document Type: Review

References (100)

1. Engels E.A., Pfeiffer R.M., Fraumeni J.F., et al. Spectrum of cancer risk among U.S. solid organ transplant recipients: the Transplant Cancer Match Study. JAMA 2011, 306:1891-1901.
2. Collett D., Mumford L., Banner N.R., Neuberger J., Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK registry audit. Am J Transplant 2010, 10:1889-1896.
3. Grulich A.E., van Leeuwen M.T., Falster M.O., Vajdic C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370:59-67.
4. Villeneuve P.J., Schaubel D.E., Fenton S.S., Shepherd F.A., Jiang Y., Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007, 7:941-948.
5. Webster A.C., Craig J.C., Simpson J.M., Jones M.P., Chapman J.R. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 2007, 7:2140-2151.
6. Adami J., Gabel H., Lindelof B., et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003, 89:1221-1227.
7. Maisonneuve P., Agodoa L., Gellert R., et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999, 354:93-99.
8. Kyllönen L., Salmela K., Pukkala E. Cancer incidence in a kidney-transplanted population. Transpl Int 2000, 13:S394-S398.
9. Li W.-H., Chen Y.-J., Tseng W.-C., et al. Malignancies after renal transplantation in Taiwan: a nationwide population-based study. Nephrol Dial Transplant 2012, 833-839.
10. Kasiske B.L., Snyder J.J., Gilbertson D.T., Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004, 4:905-913.
11. Lanza L.L., Wang L., Simon T.A., Irish W.D. Epidemiologic critique of literature on post-transplant neoplasms in solid organ transplantation. Clin Transplant 2009, 23:582-588.
12. Stewart T., Tsai S.C., Grayson H., Henderson R., Opelz G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 1995, 346:796-798.
13. Stewart J.H., Vajdic C.M., van Leeuwen M.T., et al. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant 2009, 24:3225-3231.
14. Murray K.F., Carithers R.L. AASLD practice guidelines: evaluation of the patients for liver transplantation. Hepatology 2005, 41:1-26.
15. Finkenstedt A., Graziadei I.W., Oberaigner W., et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant 2009, 9:2355-2361.
16. Wong G., Hayen A., Chapman J.R., et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol 2009, 20:1341-1350.
17. Weng P.H., Hung K.Y., Huang H.L., Chen J.H., Sung P.K., Huang K.C. Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol 2011, 6:1121-1128.
18. Pilmore H., Dent H., Chang S., McDonald S.P., Chadban S.J. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010, 89:851-857.
19. U.S.Renal Data System USRDS 2011 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States 2011, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
20. Cheung C.Y., Lam M.F., Chu K.H., et al. Malignancies after kidney transplantation: Hong Kong renal registry. Am J Transplant 2012, 12:3039-3046.
21. Na R., Grulich A.E., Meagher N.S., McCaughan G.W., Keogh A.M., Vajdic C.M. Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients. Am J Transplant 2013, 13:174-183.
22. Kiberd B.A., Rose C., Gill J.S. Cancer mortality in kidney transplantation. Am J Transplant 2009, 9:1868-1875.
23. Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009, 69:2227-2243.
24. Kauffman H.M., Cherikh W.S., McBride M.A., Cheng Y., Hanto D.W. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 2006, 19:607-620.
25. Gallagher M.P., Kelly P.J., Jardine M., et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010, 21:852-858.
26. Knight S.R., Russell N.K., Barcena L., Morris P.J. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 2009, 87:785-794.
27. Webster A.C., Ruster L.P., McGee R., et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010, 1:CD003897.
28. Sampaio M.S., Cho Y.W., Qazi Y., Bunnapradist S., Hutchinson I.V., Shah T. Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database. Transplantation 2012, 94:990-998.
29. Morgan R.D., O'Callaghan J.M., Knight S.R., Morris P.J. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation 2012, 93:1179-1188.
30. Kauffman H.M., Cherikh W.S., Cheng Y., Hanto D.W., Kahan B.D. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005, 80:883-889.
31. Webster A.C., Lee V.W., Chapman J.R., Craig J.C. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006, 81:1234-1248.
32. Alberú J., Pascoe M.D., Campistol J.M., et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011, 92:303-310.
33. Kasiske B.L., Cangro C.B., Hariharan S., et al. American Society of Transplantation. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001, 1:3-95.
34. Knoll G., Cockfield S., Blydt-Hansen T., et al. Kidney Transplant Working Group of the Canadian Society of Transplantation. Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. Can Med Assoc J 2005, 173:S1-S25.
35. CARI Guidelines Recipient assessment for transplantation Available from, [last accessed February 15, 2012]. http://www.cari.org.au/trans_recipient_suitability_underdev.php.
36. European Best Practice Guidelines (EBPG) Section I: evaluation, selection and preparation of the potential renal transplant candidate. Nephrol Dial Transplant 2000, 15:3-38.
37. Canadian Task Force on Preventive Health Care, Pollock S., Dunfield L., et al. Recommendations on screening for cervical cancer. CMAJ 2013, 185:35-45.
38. Canadian Task Force on Preventive Health Care, Tonelli M., Connor Gorber S., et al. Recommendations on screening for breast cancer in average-risk women aged 40-74years. CMAJ 2011, 183:1991-2001.
39. US Preventive Services Task Force Screening for prostate cancer: US Preventive Services Task Force recommendation statement: draft: summary of recommendation and evidence [October 7, 2011. Accessed October 17, 2012]. http://www.uspreventiveservicestaskforce.org/draftrec3.htm.
40. U.S.Preventive Services Task Force Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 149:627-637.
41. Secin F.P., Carver B., Kattan M.W., Eastham J.A. Current recommendations for delaying renal transplantation after localized prostate cancer treatment: are they still appropriate?. Transplantation 2004, 78:710-712.
42. National Lung Screening Trial Research Team, Aberle D.R., Adams A.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409.
43. Monsalve J., Kapur J., Malkin D., Babyn P.S. Imaging of cancer predisposition syndromes in children. Radiographics 2011, 31:263-280.
44. Dedhia R.C., Grandis J.R., Fontes P.A., Johnson J.T., Weissfeld J. Screening for head and neck cancer in liver transplant candidates: a review of 11years of experience at the University of Pittsburgh. Laryngoscope 2012, 122:539-542.
45. Jimenez-Zepeda V.H., Heilman R.L., Engel R.A., et al. Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants. Transplantation 2011, 92:570-574.
46. Brattström C., Granath F., Edgren G., Smedby K.E., Wilczek H.E. Overall and cause-specific mortality in transplant recipients with a pretransplantation cancer history. Transplantation 2013, 96:297-305.
47. Batabyal P., Chapman J.R., Wong G., Craig J.C., Tong A. Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable?. Transplantation 2012, 94:703-713.
48. Steinman T.I., Becker B.N., Frost A.E., et al. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001, 71:1189-1204.
49. Harden P. UK renal association guidelines [Retrieved from internet August 8, 2013]. http://www.renal.org/Libraries/Guidelines/4_-_Assessment_for_Transplantation_-_Previous_version_-_09_May_2007_DRAFT.sflb.ashx.
50. Clavien P.A., Lesurtel M., Bossuyt P.M., et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012, 13:e11-e22.
51. Nalesnik M.A., Woodle E.S., Dimaio J.M., et al. Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. Am J Transplant 2011, 11:1140-1147.
52. Kauffman H.M., McBride M.A., Cherikh W.S., Spain P.C., Marks W.H., Roza A.M. Transplant tumor registry: donor related malignancies. Transplantation 2002, 74:358-362.
53. Feng S., Buell J.F., Cherikh W.S., et al. Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation. Transplantation 2002, 74:1657-1663.
54. Kauffman H.M. The United Network for Organ Sharing position on using donors with primary central nervous system malignancies. Transplantation 2005, 79:622-623.
55. Kauffman H.M., Cherikh W.S., McBride M.A., Cheng Y., Hanto D.W. Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update. Transplantation 2007, 84:272-274.
56. [Retrieved from internet August 12, 2013]. http://news.sky.com/story/1026916/cystic-fibrosis-woman-dies-after-transplant.
57. The CARI guidelines-donor cancer [Retrieved August 8, 2013]. http://www.cari.org.au/TRANS_deceased_published/Donor_cancer_jul_2005.pdf.
58. Council of Europe International consensus document: standardisation of organ donor screening to prevent transmission of neoplastic diseases 1997, Council of Europe.
59. Buell J.F. Use of donors with central nervous system malignancies: proceed with caution. Transplantation 2004, 77:1906-1907.
60. Yin M., Bastacky S., Chandran U., Becich M.J., Dhir R. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol 2008, 179:892-895.
61. Freeman R.B., Cohen J.T. Transplantation risks and the real world: what does 'high risk' really mean?. Am J Transplant 2009, 9:23-30.
62. Halpern S.D., Shaked A., Hasz R.D., Caplan A.L. Informing candidates for solid-organ transplantation about donor risk factors. N Engl J Med 2008, 358:2832-2837.
63. Kasiske B.L., Vazquez M.A., Harmon W.E., et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 2000, 11:S1-S86.
64. EBPG Expert Group on Renal Transplantation European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: prevention and treatment. Nephrol Dial Transplant 2002, 17:34-36.
65. Kiberd B.A., Keough-Ryan T., Clase C.M. Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am J Transplant 2003, 3:619-625.
66. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009, 9:S1-S157.
67. Wong G., Howard K., Craig J.C., Chapman J.R. Cost-effectiveness of colorectal cancer screening in renal transplant recipients. Transplantation 2008, 85:532-541.
68. Wong G., Howard K., Webster A., Chapman J.R., Craig J.C. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients. Transplantation 2009, 87:1078-1091.
69. Spier B.J., Walker A.J., Cornett D.D., Pfau P.R., Halberg R.B., Said A. Screening colonoscopy and detection of neoplasia in asymptomatic, average-risk, solid organ transplant recipients: case-control study. Transpl Int 2010, 23:1233-1238.
70. Collins M.G., Teo E., Cole S.R., et al. Screening for colorectal cancer and advanced colorectal neoplasia in kidney transplant recipients: cross sectional prevalence and diagnostic accuracy study of faecal immunochemical testing for haemoglobin and colonoscopy. BMJ 2012, 345:e4657.
71. Webster A.C., Wong G., Craig J.C., Chapman J.R. Managing cancer risk and decision making after kidney transplantation. Am J Transplant 2008, 8:2185-2191.
72. Wong G., Chapman J.R., Craig J.C. Cancer screening in renal transplant recipients: what is the evidence?. Clin J Am Soc Nephrol 2008, 3:S87-S100.
73. Bruix J., Sherman M. Management of hepatocelluar carcinoma. Hepatology 2005, 42:1208-1235.
74. Ramsay H.M., Fryer A.A., Hawley C.M., Smith A.G., Harden P.N. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002, 147:950-956.
75. Mackenzie K.A., Wells J.E., Lynn K.L., et al. First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients. Nephrol Dial Transplant 2010, 25:300-306.
76. Schober T., Framke T., Kreipe H., et al. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation 2013, 95:240-246.
77. Sampaio M.S., Cho Y.W., Shah T., Bunnapradist S., Hutchinson I.V. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Nephrol Dial Transplant 2012, 27:2971-2979.
78. Green M., Michaels M.G. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant 2013, 13:41-54.
79. Penn I. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant 1998, 2:56-63.
80. Opelz G., Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004, 4:222-230.
81. Bustami R.T., Ojo A.O., Wolfe R.A., et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004, 4:87-93.
82. Dharnidharka V.R., Lamb K.E., Gregg J.A., Meier-Kriesche H.U. Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States. Am J Transplant 2012, 12:976-983.
83. Quinlan S.C., Pfeiffer R.M., Morton L.M., Engels E.A. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011, 86:206-209.
84. Sampaio M.S., Cho Y.W., Shah T., Bunnapradist S., Hutchinson I.V. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Transplantation 2012, 93:73-81.
85. Vincenti F., Charpentier B., Vanrenterghem Y., et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010, 10:535-546.
86. Gulley M.L., Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 2010, 23:350-366.
87. Lim W.H., Russ G.R., Coates P.T.H. Review of Epstien-Barr virus and post transplant lymphoproliferative disorder post-solid organ transplantation. Nephrology 2006, 11:355-366.
88. Schwarz A., Vatandaslar S., Merkel S., Haller H. Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol 2007, 2:750-756.
89. Vajdic C.M., McDonald S.P., McCredie M.R., et al. Cancer incidence before and after kidney transplantation. JAMA 2006, 296:2823-2831.
90. Tsivian M., Caso J.R., Kimura M., Polascik T. Renal tumors in solid organ recipients: clinical and pathologic features. J Urol Oncol 2013, 31:255-258.
91. Klatte T., Seitz C., Waldert M., et al. Features and outcomes of renal cell carcinoma of native kidneys in renal transplant recipients. BJU Int 2010, 105:1260-1265.
92. Wong G., Howard K., Webster A.C., Chapman J.R., Craig J.C. Screening for renal cancer in recipients of kidney transplants. Nephrol Dial Transplant 2011, 26:1729-1739.
93. Augustine J.J., Woodside K.J., Padiyar A., Sanchez E.Q., Hricik D.E., Schulak J.A. Independent of nephrectomy, weaning immunosuppression leads to late sensitization after kidney transplant failure. Transplantation 2012, 94:738-743.
94. van Leeuwen M.T., Webster A.C., McCredie M.R., et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ Feb 11 2010, 340:570.
95. Euvrard S., Morelon E., Rostaing L., et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012, 367:329-339.
96. Campbell S.B., Walker R., Tai S.S., Jiang Q., Russ G.R. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012, 12:1146-1156.
97. Khokhar N.Z., Altman J.K., Platanias L.C. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opin Oncol 2011, 23:578-586.
98. Baldo P., Cecco S., Giacomin E., Lazzarini R., Ros B., Marastoni S. mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets 2008, 8:647-665.
99. Bray F., Ren J.S., Masuyer E., Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013, 132:1133-1145.
100. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993, 55:742-747.